Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714191 · ClinicalTrials.gov registry record
Optimizing the Tobacco Cessation Clinical Decision Support Tool.
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 54,417
- Enrollment target
NCT03714191: Completed study, sponsored by NYU Langone Health.
NCT03714191 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 54,417 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03714191 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 54,417 participants
- Enrollment target
Study Summary
The existing tobacco cessation best practice advisory (BPA) fires for providers (physicians, residents, fellows, midwives, nurse practitioners, physician assistants) during outpatient encounters when a patient is identified as a current tobacco user in the Social History section of their chart. The BPA was designed to help facilitate tobacco cessation interventions; it is part of the The Centers for Medicare \& Medicaid Services (CMS) Quality Payment Program (QPP). The purpose of the project is to optimize this BPA utilization and improve patient outcomes by comparing multiple versions of the tobacco cessation BPA.
Interventions
- OTHER Patient Outcomes
- OTHER Billing documentation
- OTHER Regulatory
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54,417 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2020-02-29 |
What the finished NCT03714191 record still lists
NCT03714191 is an observational study that tracks outcomes without assigning an intervention. Its 54,417 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Patient Outcomes is the first listed.
NCT03714191 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03714191 about?
NCT03714191 is a clinical study titled "Optimizing the Tobacco Cessation Clinical Decision Support Tool.". The existing tobacco cessation best practice advisory (BPA) fires for providers (physicians, residents, fellows, midwives, nurse practitioners, physician assistants) during outpatient encounters when a patient is identified as a current tobacco user in the Social History section of their chart. The ...
What is the current status of trial NCT03714191?
This trial is currently completed. The enrollment target is 54,417 participants. The study started on 2018-10-03. Estimated completion is 2020-02-29.
What interventions are being tested in trial NCT03714191?
The interventions under investigation include: Patient Outcomes (OTHER), Billing documentation (OTHER), Regulatory (OTHER).
Who is sponsoring clinical trial NCT03714191?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI